Reviva Pharmaceuticals
OTC: RVPHSanta Clara, US · Founded 2018 · Delaware corporation · 1 known investors
Reviva Pharmaceuticals is a clinical-stage drug developer with a pipeline of two in-house-discovered new chemical entities, brilaroxazine (RP5063) and RP1208, developed using its chemical genomics platform. Its lead candidate, brilaroxazine, is being developed for schizophrenia and has completed a Phase 3 trial.
Founders & leadership
Reviva Pharmaceuticals was founded in 2018 by Laxminarayan Bhat.
LB
Laxminarayan BhatFounder, President and Chief Executive Officer
MC
Marc CantillonExecutive
NP
Narayan PrabhuExecutive
PP
Purav PatelNamed on SEC filing
LF
Les FuntleyderNamed on SEC filing
RM
Richard MargolinNamed on SEC filing
Board
PS
SD
Sarvajna DwivediBoard director
PJ
Pedr JensenBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$17M disclosed across 2 of 4 rounds · 2014–2026
▶Undisclosed amountofferedSep 2022 · 3 investors · PharmaceuticalsRule 506(b)
▶Undisclosed amountofferedSep 2022 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Purav PatelDirector
- Narayan PrabhuExecutive Officer
- Parag SaxenaDirector
- Les FuntleyderDirector
- Richard MargolinDirector
- Laxminarayan BhatExecutive Officer, Director
- Placement agents
- A.G.P./Alliance Global Partners
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$1.2MraisedJul 2016 · 16 investors · PharmaceuticalsRule 506(c)
▶$1.2MraisedJul 2016 · 16 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Laxminarayan BhatExecutive Officer, Director
- Marc CantillonExecutive Officer
- Sarvajna DwivediDirector
- Pedr JensenDirector
- Offering amount
- $5M
- Amount sold
- $1.2M
- Minimum investment
- $25K
- Sales commissions
- $150K
- Placement agents
- Rodman & Renshaw, a unit of H.C. Wainwright & Co, LLC
- First sale
- Jul 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$15.8MraisedJun 2014 · 47 investors · PharmaceuticalsRule 506(c)
▶$15.8MraisedJun 2014 · 47 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Laxminarayan BhatExecutive Officer, Director
- Offering amount
- $15.8M
- Amount sold
- $15.8M
- First sale
- Jun 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 7
by search overlap
Seeking Alpha50 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Simply Wall St38 shared keywordsSimply Wall St is a stock analysis platform that provides portfolio insights, stock discovery tools, and market alerts for individual investors. The service offers institutional-grade financial data visualization and analysis across 120,000 global stocks.
TipRanks35 shared keywordsFinancial analysis and stock research platform.
Robinhood34 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
StockTwits32 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Perplexity28 shared keywordsAn AI-powered answer engine providing accurate, trusted, and real-time answers to questions.
TradingView26 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Companies competing with Reviva Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Reviva Pharmaceuticals do?
- Reviva Pharmaceuticals is a clinical-stage drug developer with a pipeline of two in-house-discovered new chemical entities, brilaroxazine (RP5063) and RP1208, developed using its chemical genomics platform. Its lead candidate, brilaroxazine, is being developed for schizophrenia and has completed a Phase 3 trial.
- Who founded Reviva Pharmaceuticals?
- Reviva Pharmaceuticals was founded by Laxminarayan Bhat in 2018.
- Who are Reviva Pharmaceuticals's investors?
- Reviva Pharmaceuticals's investors include Vedanta Capital.
- How much funding has Reviva Pharmaceuticals raised?
- Reviva Pharmaceuticals has disclosed $17M raised across 2 of its 4 known rounds.
- Where is Reviva Pharmaceuticals headquartered?
- Reviva Pharmaceuticals is headquartered in Santa Clara, US.